GLP-1 for Young Adults (18-25): What to Consider

If you are between 18 and 25 and considering a GLP-1 medication like semaglutide or tirzepatide for weight management, you are not alone. Young adults are one of the fastest-growing demographics seeking these medications, driven by both rising obesity rates in this age group and increased awareness through social media. But younger patients face unique considerations that do not always get addressed in conversations dominated by middle-aged treatment data. This guide covers what you specifically need to know — from eligibility and long-term safety to body image, fertility, and navigating treatment during some of the most transitional years of your life.

Are You Eligible? Understanding the Medical Criteria

GLP-1 medications for weight management are FDA-approved for adults 18 and older (semaglutide under the brand name Wegovy is also approved for adolescents 12 and older). The standard medical criteria for weight management prescribing include a BMI of 30 or greater (obesity), or a BMI of 27 or greater with at least one weight-related health condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnea.

For young adults, meeting BMI thresholds does not automatically mean medication is the right first step. Most providers prefer to see evidence that structured lifestyle interventions — including dietary changes, regular exercise, behavioral therapy, and adequate sleep — have been attempted and proved insufficient before prescribing medication. This is not gatekeeping; it is sound medical practice. Lifestyle foundations remain essential even when taking GLP-1 medications, and patients who build these habits first tend to have better long-term outcomes.

That said, some young adults have clinical obesity with genuine health consequences that warrant earlier pharmacological intervention. If you have been struggling with weight since childhood, have a family history of severe obesity, or are already developing metabolic complications, medication may be appropriate even at a younger age. The key is a thorough evaluation by a qualified provider. Learn more about eligibility on our treatments page.

Long-Term Safety: What We Know and What We Do Not

One of the most significant concerns for young adults is that GLP-1 medications are relatively new for weight management. Semaglutide was FDA-approved for obesity in 2021, and tirzepatide in 2023. While safety data from diabetes use extends back further (liraglutide since 2010, semaglutide since 2017), the longest weight-management studies span approximately 4 to 5 years.

For a 20-year-old, "long-term" means potentially decades of use. The honest answer is that we do not have 20- or 30-year safety data because the medications have not existed that long. What we do know is encouraging: GLP-1 receptor agonists have shown consistent safety profiles in available studies, with cardiovascular benefits demonstrated in the SELECT trial, and no signal of increased cancer risk in human studies to date.

However, important uncertainties remain:

• Bone density: Rapid weight loss at any age can decrease bone mineral density. For young adults who may not have reached peak bone mass (which typically occurs around age 25-30), this is a consideration that should be monitored.
• Muscle mass: Young adults are in their prime muscle-building years. Semaglutide-induced weight loss includes some lean mass loss (approximately 25-40% of total weight lost), which is important to minimize through resistance training and adequate protein intake.
• Pancreatic health: Animal studies showed thyroid tumors with GLP-1 agonists in rodents, leading to a boxed warning. This has not been replicated in human studies, but it remains a monitored concern.
• Discontinuation effects: Studies show that most weight is regained within 1 to 2 years of stopping GLP-1 medications. For young adults, this raises questions about treatment duration and exit strategies.

Body Image and Social Media Pressures

Young adults today face unique body image pressures that previous generations did not. Social media creates constant exposure to idealized body types, and "Ozempic" has become a cultural phenomenon with its own complicated social dynamics. Before starting a GLP-1 medication, it is worth honestly examining your motivations:

• Are you seeking treatment for genuine health concerns, or are you trying to meet an aesthetic ideal that may not be medically necessary?
• Is your perception of your weight aligned with medical reality, or has it been distorted by social media comparisons?
• Do you have a history of disordered eating, body dysmorphia, or an eating disorder? (If so, read our guide on GLP-1 medications and eating disorder history.)
• Are you prepared for the reality that GLP-1 medications produce gradual, moderate weight loss — not the dramatic transformations often showcased on social media?

There is no shame in wanting to improve your health and feel more comfortable in your body. But medical weight management works best when driven by health goals rather than purely aesthetic ones, and when expectations are grounded in reality rather than social media highlight reels.

Fertility and Reproductive Health Considerations

This is one of the most important and under-discussed topics for young adults on GLP-1 medications.

For women and people who can become pregnant

Semaglutide and tirzepatide are not recommended during pregnancy or while breastfeeding. Current guidelines recommend stopping GLP-1 medications at least 2 months before a planned pregnancy (some providers recommend longer for tirzepatide due to its longer half-life). Reliable contraception is essential during treatment.

An important and sometimes surprising effect: weight loss itself can improve fertility. Women with obesity-related anovulation (irregular or absent ovulation) may resume ovulating as they lose weight on semaglutide, potentially leading to unplanned pregnancy. Multiple case reports have documented this phenomenon. If you are sexually active and not using reliable contraception, discuss this with your provider before starting treatment.

The effects on egg quality and future fertility are not well studied. While there is no evidence of harm, the lack of long-term data means this is a conversation to have with your provider, especially if you plan to become pregnant in the next few years.

For men

Some research suggests that GLP-1 medications may actually improve male reproductive health by reducing obesity-related hormonal imbalances. Obesity is associated with lower testosterone levels, and weight loss often normalizes testosterone. However, rapid weight loss from any cause can temporarily suppress reproductive hormones. If fertility is a concern, have your hormone levels monitored during treatment.

Practical Considerations for College Students and Young Professionals

Life between 18 and 25 is often characterized by irregular schedules, limited budgets, social eating and drinking, and frequent transitions. Here is how these realities intersect with GLP-1 treatment:

Cost and insurance

GLP-1 medications can be expensive, and many young adults are on their parents' insurance, transitioning off family plans, or have limited coverage through employer or university health plans. Check your specific coverage before starting treatment. Some telehealth providers, including Trimi, offer more accessible pricing than traditional clinics. Visit our treatments page for current pricing information.

Alcohol and social life

Many semaglutide users report significantly reduced alcohol tolerance. What previously felt like two drinks may now feel like four. This is partly due to slowed gastric emptying (alcohol sits in the stomach longer, potentially increasing absorption) and partly due to reduced body weight. For young adults in social environments where drinking is common, this requires honest awareness and adjustment. Reduced alcohol consumption is generally a health positive, but impaired tolerance without awareness can be dangerous.

Meal timing and dining halls

College dining halls and irregular schedules make consistent nutrition challenging. Focus on protein-first eating at every meal, stay hydrated, and do not skip meals entirely even when appetite is suppressed. Your body still needs fuel for brain function, studying, and physical activity.

Exercise

Young adults have a significant advantage: you can build muscle more efficiently than older adults. Take full advantage of this by prioritizing resistance training alongside your GLP-1 treatment. Even 2 to 3 sessions per week of strength training can dramatically improve body composition outcomes and help ensure that the weight you lose is primarily fat, not muscle. Learn more on our how it works page.

Mental Health Considerations

The 18-25 age range is a critical period for mental health. Rates of anxiety, depression, and eating disorders peak during this time. GLP-1 medications can interact with mental health in complex ways:

• Weight loss can improve self-esteem and reduce weight-related social anxiety.
• The loss of food as an emotional coping mechanism can be destabilizing if alternative coping strategies are not in place.
• Some patients report mood changes (both positive and negative) on GLP-1 medications, though large-scale studies have not found a consistent link to depression or suicidal ideation.
• Rapid changes in body shape can trigger identity questions and unexpected emotional responses.

If you are currently managing a mental health condition, discuss GLP-1 medications with both your prescribing provider and your mental health provider. An integrated approach leads to better outcomes.

Setting Realistic Expectations

Clinical trials show that semaglutide 2.4 mg produces an average weight loss of approximately 15% of body weight over 68 weeks, and tirzepatide produces approximately 20 to 25% at the highest doses. These are averages — individual results vary widely. For a 220-pound young adult, a 15% loss means reaching approximately 187 pounds, not 150.

Weight loss on GLP-1 medications is gradual. Most patients lose 1 to 2 pounds per week during the active weight loss phase, with results plateauing after 12 to 18 months. Social media often compresses months of progress into single before-and-after images, creating an unrealistic perception of speed.

Additionally, these medications are most effective as part of a comprehensive approach that includes nutrition, exercise, sleep, and behavioral changes. They are not a substitute for building healthy habits — they are a tool that makes building those habits easier by reducing the constant struggle with appetite and cravings.

When GLP-1 Medications May Not Be Right for You

Despite their effectiveness, GLP-1 medications are not appropriate for every young adult. Consider holding off if:

• Your BMI is below the clinical criteria and your motivation is primarily cosmetic.
• You have not yet tried structured lifestyle changes with professional guidance.
• You have an active eating disorder (anorexia nervosa, bulimia, or active binge eating disorder without medical supervision).
• You are pregnant, planning to become pregnant soon, or breastfeeding.
• You have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• You cannot commit to ongoing medical follow-up and monitoring.

Frequently Asked Questions

Can you take semaglutide at 18?

Yes. Semaglutide (Wegovy) is FDA-approved for weight management in adults 18 and older who meet BMI criteria. It is also approved for adolescents 12 and older for weight management. However, age eligibility does not mean it is automatically appropriate — a thorough medical evaluation should determine if it is the right choice for your individual situation.

Is it safe to take GLP-1 medications long-term as a young adult?

Current evidence supports the safety of GLP-1 medications over the available study periods (up to approximately 4-5 years for weight management). However, we lack multi-decade safety data. Most providers consider the known health risks of untreated obesity to outweigh the theoretical risks of long-term GLP-1 use, but this risk-benefit analysis should be individualized. Regular monitoring with your provider helps catch any issues early.

Will I have to take semaglutide forever?

Current evidence suggests that obesity is a chronic condition for most people, and discontinuing GLP-1 medications typically leads to weight regain. However, this does not necessarily mean lifelong use at the same dose. Some patients successfully transition to lower maintenance doses or periodic treatment. Research on optimal long-term strategies for young adults is ongoing. The best approach is to build strong lifestyle habits during treatment so that, if you do stop, the weight regain is minimized.

Will GLP-1 medications affect my ability to have children later?

There is no evidence that GLP-1 medications permanently affect fertility in men or women. However, these medications should be discontinued before pregnancy. For women, improved fertility during treatment (due to weight loss) is actually a risk factor for unplanned pregnancy. Discuss family planning with your provider and use reliable contraception during treatment.

Can I drink alcohol on semaglutide?

There is no absolute contraindication to alcohol use with semaglutide, but most users report significantly reduced alcohol tolerance. Drinks hit harder and faster. Start slowly, stay well-hydrated, and be aware that alcohol provides empty calories that can slow your weight loss progress. Binge drinking is particularly risky on GLP-1 medications due to the combination of slowed gastric emptying and increased intoxication effects.

How do I talk to my doctor about wanting GLP-1 medications?

Be direct and honest about your weight history, what you have already tried, and your health goals. A good provider will take your concerns seriously regardless of your age. If your primary care provider is dismissive, seeking a second opinion or consulting with a weight management specialist is reasonable. You can also explore telehealth options like Trimi for a comprehensive evaluation.